Abstract
Metabolic deregulation is a key factor in cancer progression. Epigenetic changes and metabolic rewiring are intertwined in cancer. Deregulated epigenetic modifiers cause metabolic aberrations by targeting the expression of metabolic enzymes. Conversely, metabolites and cofactors affect the expression and activity of epigenetic regulators. Small molecules are promising therapeutic approaches to target the epigenetic-metabolomic crosstalk in cancer. Here, we focus on the interplay between metabolic rewiring and epigenetic landscape in the context of tumourigenesis and highlight recent advances in the use of small-molecule drug targets for therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agios Pharmaceuticals, Inc. (2018a) A phase 1, open-label, single-dose study to evaluate the pharmacokinetics, safety, and tolerability of AG-120 (Ivosidenib) in subjects with mild or moderate hepatic impairment or normal hepatic function. clinicaltrials.gov
Agios Pharmaceuticals, Inc. (2018b) Expanded access program for Ivosidenib (AG-120) monotherapy in patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. clinicaltrials.gov
Agios Pharmaceuticals, Inc. (2019) A phase I, multicenter, open-label, dose-escalation and expansion, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-881 in patients with advanced hematologic malignancies with an IDH1 and/or IDH2 mutation. clinicaltrials.gov
Agios Pharmaceuticals, Inc. (2020a) A phase 1, multicenter, randomized, controlled, open-label, perioperative study of AG-120 and AG-881 in subjects with recurrent, non-enhancing, IDH1 mutant, low grade glioma. clinicaltrials.gov
Agios Pharmaceuticals, Inc. (2020b) A phase 1, multicenter, open-label, dose-escalation and expansion, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-881 in patients with advanced solid tumors, including gliomas, with an IDH1 and/or IDH2 mutation. clinicaltrials.gov
Agios Pharmaceuticals, Inc. (2020c) A phase 3, multicenter, randomized, double-blind, placebo- controlled study of AG-881 in subjects with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation. clinicaltrials.gov
Ahmad A, Aboukameel A, Kong D et al (2011) Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 71:3400–3409. https://doi.org/10.1158/0008-5472.CAN-10-0965
Albrecht BK, Gehling VS, Hewitt MC et al (2016) Identification of a Benzoisoxazoloazepine inhibitor (CPI-0610) of the Bromodomain and extra-terminal (BET) family as a candidate for human clinical trials. J Med Chem 59:1330–1339. https://doi.org/10.1021/acs.jmedchem.5b01882
Amorim S, Stathis A, Gleeson M et al (2016) Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol 3:e196–e204. https://doi.org/10.1016/S2352-3026(16)00021-1
Avery LB, Bumpus NN (2014) Valproic acid is a novel activator of AMP-activated protein kinase and decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice. Mol Pharmacol 85:1–10. https://doi.org/10.1124/mol.113.089755
Bajor D (2020) Phase I/II study of CB-839 and capecitabine in patients with advanced solid tumors and fluoropyrimidine resistant PIK3CA mutant colorectal cancer. clinicaltrials.gov
Bayer (2019) An open-label, non-randomized, multicenter phase I study to determine the maximum tolerated and/or recommended phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY1436032 and to characterize its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy in patients with mIDH1-R132X advanced Acute Myeloid Leukemia (AML). clinicaltrials.gov
Bayer (2020) An open-label, non-randomized, multicenter phase i study to determine the maximum tolerated or recommended phase II dose of oral mutant IDH1 inhibitor BAY1436032 and to characterize its safety, tolerability, pharmacokinetics and preliminary pharmacodynamic and anti-tumor activity in patients with IDH1-R132X-mutant advanced solid tumors. clinicaltrials.gov
Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11:726–734. https://doi.org/10.1038/nrc3130
Baylin SB, Jones PA (2016) Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol 8:a019505. https://doi.org/10.1101/cshperspect.a019505
Berenguer-Daizé C, Astorgues-Xerri L, Odore E et al (2016) OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. Int J Cancer 139:2047–2055. https://doi.org/10.1002/ijc.30256
Berthon C, Raffoux E, Thomas X et al (2016) Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol 3:e186–e195. https://doi.org/10.1016/S2352-3026(15)00247-1
Best JD, Carey N (2010) Epigenetic opportunities and challenges in cancer. Drug Discov Today 15:65–70. https://doi.org/10.1016/j.drudis.2009.10.010
Boi M, Gaudio E, Bonetti P et al (2015) The BET Bromodomain inhibitor OTX015 affects Pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res 21:1628–1638. https://doi.org/10.1158/1078-0432.CCR-14-1561
Calin GA, Cimmino A, Fabbri M et al (2008) MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A 105:5166–5171. https://doi.org/10.1073/pnas.0800121105
Calithera Biosciences, Inc (2017) A phase 1 study of the safety, pharmacokinetics, and pharmacodynamics of escalating oral doses of the glutaminase inhibitor CB-839 in patients with relapsed and/or treatment-refractory leukemia. clinicaltrials.gov
Calithera Biosciences, Inc (2018) A phase 1 study of the safety, pharmacokinetics, and pharmacodynamics of escalating oral doses of the glutaminase inhibitor CB-839 in patients with advanced and/or treatment-refractory hematological malignancies. clinicaltrials.gov
Calvert AE, Chalastanis A, Wu Y et al (2017) Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation. Cell Rep 19:1858–1873. https://doi.org/10.1016/j.celrep.2017.05.014
Cantor JR, Sabatini DM (2012) Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2:881–898. https://doi.org/10.1158/2159-8290.CD-12-0345
Caponigro F, Di Gennaro E, Ionna F et al (2016) Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of head and neck-V- CHANCE trial. BMC Cancer 16:918. https://doi.org/10.1186/s12885-016-2957-y
Celgene (2018) A phase 1/2, multicenter, open-label, dose-escalation study of AG-221 in subjects with advanced solid tumors, including glioma, and with angioimmunoblastic T-cell lymphoma, that harbor an IDH2 mutation. clinicaltrials.gov
Celgene (2019) A single agent phase II study of depsipeptide (FK228) in the treatment of cutaneous T-cell lymphoma. clinicaltrials.gov
Celgene (2020) A phase 1/2, multicenter, open-label, dose-escalation and expansion, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG- 221 in subjects with advanced hematologic malignancies with an IDH2 mutation. clinicaltrials.gov
Chen W, Guéron M (1992) The inhibition of bovine heart hexokinase by 2-deoxy-d-glucose-6- phosphate: characterization by 31P NMR and metabolic implications. Biochimie 74:867–873. https://doi.org/10.1016/0300-9084(92)90070-U
Chen D-H, Wu K-T, Hung C-J et al (2004) Effects of adenosine dialdehyde treatment on in vitro and in vivo stable protein methylation in HeLa cells. J Biochem 136:371–376. https://doi.org/10.1093/jb/mvh131
Chen M, Zhang J, Li N et al (2011) Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS One 6:e25564. https://doi.org/10.1371/journal.pone.0025564
Chen Q, Chen Y, Bian C et al (2013a) TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 493:561–564. https://doi.org/10.1038/nature11742
Chen Y-H, Heneidi S, Lee J-M et al (2013b) miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes 62:2278–2286. https://doi.org/10.2337/db12-0963
Chen J, Yang J, Sun X et al (2017) Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q. Sci Rep 7:16458. https://doi.org/10.1038/s41598-017-16427-w
Chien W, Lee DH, Zheng Y et al (2014) Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Mol Carcinog 53:722–735. https://doi.org/10.1002/mc.22024
Christman JK (2002) 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21:5483–5495. https://doi.org/10.1038/sj.onc.1205699
Chu C-S, Lo P-W, Yeh Y-H et al (2014) O-GlcNAcylation regulates EZH2 protein stability and function. Proc Natl Acad Sci U S A 111:1355–1360. https://doi.org/10.1073/pnas.1323226111
Chuang T-Y, Wu H-L, Chen C-C et al (2015) MicroRNA-223 expression is upregulated in insulin resistant human adipose tissue. J Diabetes Res 2015:943659. https://doi.org/10.1155/2015/943659
Cluntun AA, Huang H, Dai L et al (2015) The rate of glycolysis quantitatively mediates specific histone acetylation sites. Cancer Metab 3:10. https://doi.org/10.1186/s40170-015-0135-3
Constellation Pharmaceuticals (2020) A phase 1/2 study of CPI-0610, a small molecule inhibitor of BET proteins: phase 1 (in patients with hematological malignancies) and phase 2 (dose expansion of CPI-0610 with and without ruxolitinib in patients with myelofibrosis). clinicaltrials.gov
Coudé M-M, Braun T, Berrou J et al (2015) BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget 6:17698–17712. https://doi.org/10.18632/oncotarget.4131
Currie E, Schulze A, Zechner R et al (2013) Cellular fatty acid metabolism and cancer. Cell Metab 18:153–161. https://doi.org/10.1016/j.cmet.2013.05.017
Dai D-W, Lu Q, Wang L-X et al (2013) Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM. BMC Cancer 13:478. https://doi.org/10.1186/1471-2407-13-478
Dang CV (2010) Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle 9:3884–3886. https://doi.org/10.4161/cc.9.19.13302
Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2- hydroxyglutarate. Nature 462:739–744. https://doi.org/10.1038/nature08617
Davis MI, Gross S, Shen M et al (2014) Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J Biol Chem 289:13717–13725. https://doi.org/10.1074/jbc.M113.511030
Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150:12–27. https://doi.org/10.1016/j.cell.2012.06.013
Delmore JE, Issa GC, Lemieux ME et al (2011) BET Bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146:904–917. https://doi.org/10.1016/j.cell.2011.08.017
Deng G, Shen J, Yin M et al (2015) Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J Biol Chem 290:762–774. https://doi.org/10.1074/jbc.M114.608497
Derissen EJB, Beijnen JH, Schellens JHM (2013) Concise drug review: azacitidine and decitabine. Oncologist 18:619–624. https://doi.org/10.1634/theoncologist.2012-0465
Desai S, Ding M, Wang B et al (2013) Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 5:8202–8210
Ding J, Li T, Wang X et al (2013) The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. Cell Metab 18:896–907. https://doi.org/10.1016/j.cmet.2013.11.004
Dong Y, Huaying S, Danying W et al (2018) Significance of methylation of FBP1 gene in non-small cell lung cancer. Biomed Res Int 2018:3726091. https://doi.org/10.1155/2018/3726091
Elhammali A, Ippolito JE, Collins L et al (2014) A high-throughput fluorimetric assay for 2- hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov 4:828–839. https://doi.org/10.1158/2159-8290.CD-13-0572
Fang R, Xiao T, Fang Z et al (2012) MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem 287:23227–23235. https://doi.org/10.1074/jbc.M112.373084
Fang E, Wang J, Hong M et al (2019) Valproic acid suppresses Warburg effect and tumor progression in neuroblastoma. Biochem Biophys Res Commun 508:9–16. https://doi.org/10.1016/j.bbrc.2018.11.103
Fei X, Qi M, Wu B et al (2012) MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. FEBS Lett 586:392–397. https://doi.org/10.1016/j.febslet.2012.01.006
Fong JJ, Nguyen BL, Bridger R et al (2012) β-N-Acetylglucosamine (O-GlcNAc) is a novel regulator of mitosis-specific Phosphorylations on histone H3. J Biol Chem 287:12195–12203. https://doi.org/10.1074/jbc.M111.315804
Forma Therapeutics, Inc. (2019) A phase 1/2, multicenter, open-label study of FT-2102 as a single agent and in combination with azacitidine or cytarabine in patients with acute myeloid leukemia or myelodysplastic syndrome with an IDH1 mutation. clinicaltrials.gov
Forma Therapeutics, Inc. (2020) A phase 1b/2 study of FT 2102 in participants with advanced solid tumors and gliomas with an IDH1 mutation. clinicaltrials.gov
Foss FM, Querfeld C, Kim YH et al (2018) Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL. JCO 36:2511–2511. https://doi.org/10.1200/JCO.2018.36.15_suppl.2511
Fujiki R, Hashiba W, Sekine H et al (2011) GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature 480:557–560. https://doi.org/10.1038/nature10656
Galloway TJ, Wirth LJ, Colevas AD et al (2015) A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with Chemoradiation in patients with head and neck squamous cell carcinoma. Clin Cancer Res 21:1566–1573. https://doi.org/10.1158/1078-0432.CCR-14-2820
Gambichler T, Sand M, Skrygan M (2013) Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma. Melanoma Res 23:218–220. https://doi.org/10.1097/CMR.0b013e32835f9bd4
Gan L, Yang Y, Li Q et al (2018) Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomarker Research 6:10. https://doi.org/10.1186/s40364-018-0122-2
Gao P, Tchernyshyov I, Chang T-C et al (2009) C-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458:762–765. https://doi.org/10.1038/nature07823
GarcÃa JM, Silva J, Peña C et al (2004) Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosom Cancer 41:117–124. https://doi.org/10.1002/gcc.20062
Gilead Sciences (2019) A phase 1b/2 study of GS-5829 in combination with fulvestrant or exemestane in subjects with advanced estrogen receptor positive, HER2 negative-breast cancer. clinicaltrials.gov
Glazer RI, Hartman KD, Knode MC et al (1986) 3-deazaneplanocin: a new and potent inhibitor of S- adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 135:688–694. https://doi.org/10.1016/0006-291x(86)90048-3
Godlewski J, Bronisz A, Nowicki MO et al (2010) microRNA-451: a conditional switch controlling glioma cell proliferation and migration. Cell Cycle 9:2742–2748
Goel A, Mathupala SP, Pedersen PL (2003) Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem 278:15333–15340. https://doi.org/10.1074/jbc.M300608200
Golub D, Iyengar N, Dogra S et al (2019) Mutant Isocitrate dehydrogenase inhibitors as targeted cancer Therapeutics. Front Oncol 9:417. https://doi.org/10.3389/fonc.2019.00417
Greer EL, Shi Y (2012) Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 13:343–357. https://doi.org/10.1038/nrg3173
Gregersen LH, Jacobsen A, Frankel LB et al (2012) MicroRNA-143 down-regulates hexokinase 2 in colon cancer cells. BMC Cancer 12:232. https://doi.org/10.1186/1471-2407-12-232
Gross MI, Demo SD, Dennison JB et al (2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 13:890–901. https://doi.org/10.1158/1535-7163.MCT-13-0870
Groupe Francophone des Myelodysplasies (2020) A single-arm phase II multicenter study of IDH2 (AG-221) inhibitor in patients with IDH2 mutated myelodysplastic syndrome. clinicaltrials.gov
Guo JU, Su Y, Zhong C et al (2011) Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145:423–434. https://doi.org/10.1016/j.cell.2011.03.022
Gupta V, Gopinath P, Iqbal MA et al (2014) Interplay between epigenetics & cancer metabolism. Curr Pharm Des 20:1706–1714. https://doi.org/10.2174/13816128113199990536
H. Lee Moffitt Cancer Center and Research Institute (2014) Phase II trial of Suberoylanilide Hydroxamic acid (SAHA, Vorinostat) in combination with tamoxifen for patients with advanced breast cancer who have failed prior anti-hormonal therapy. clinicaltrials.gov
Haematology-Oncology (2013) Phase I/II clinical trial of vorinostat in patients with recurrent and/or metastatic breast cancer. clinicaltrials.gov
Hainsworth JD, Infante JR, Spigel DR et al (2011) A phase II trial of Panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Investig 29:451–455. https://doi.org/10.3109/07357907.2011.590568
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Herman JG, Latif F, Weng Y et al (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91:9700–9704. https://doi.org/10.1073/pnas.91.21.9700
Issa J-PJ, Kantarjian HM, Kirkpatrick P (2005) Azacitidine. Nat Rev Drug Discov 4:275–276. https://doi.org/10.1038/nrd1698
Ito S, D’Alessio AC, Taranova OV et al (2010) Role of Tet proteins in 5mC to 5hmC conversion, ES- cell self-renewal and inner cell mass specification. Nature 466:1129–1133. https://doi.org/10.1038/nature09303
Ito R, Katsura S, Shimada H et al (2014) TET3-OGT interaction increases the stability and the presence of OGT in chromatin. Genes Cells 19:52–65. https://doi.org/10.1111/gtc.12107
Jarome TJ, Perez GA, Hauser RM et al (2018) EZH2 methyltransferase activity controls Pten expression and mTOR signaling during fear memory reconsolidation. J Neurosci 38:7635–7648. https://doi.org/10.1523/JNEUROSCI.0538-18.2018
Jiang S, Zhang L-F, Zhang H-W et al (2012) A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 31:1985–1998. https://doi.org/10.1038/emboj.2012.45
Jin L, Alesi GN, Kang S (2016) Glutaminolysis as a target for cancer therapy. Oncogene 35:3619–3625. https://doi.org/10.1038/onc.2015.447
Jin F, Wang Y, Zhu Y et al (2017) The miR-125a/HK2 axis regulates cancer cell energy metabolism reprogramming in hepatocellular carcinoma. Sci Rep 7:3089. https://doi.org/10.1038/s41598-017-03407-3
Johannessen T-CA, Mukherjee J, Viswanath P et al (2016) Rapid conversion of mutant IDH1 from driver to passenger in a model of human Gliomagenesis. Mol Cancer Res 14:976–983. https://doi.org/10.1158/1541-7786.MCR-16-0141
Johnson C, Warmoes MO, Shen X, Locasale JW (2015) Epigenetics and cancer metabolism. Cancer Lett 356:309–314. https://doi.org/10.1016/j.canlet.2013.09.043
Kalac M, Scotto L, Marchi E et al (2011) HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 118:5506–5516. https://doi.org/10.1182/blood-2011-02-336891
Kernytsky A, Wang F, Hansen E et al (2015) IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood 125:296–303. https://doi.org/10.1182/blood-2013-10-533604
Kim J, Dang CV (2006) Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 66:8927–8930. https://doi.org/10.1158/0008-5472.CAN-06-1501
Kim H-J, Choi BY, Keum Y-S (2015) Identification of a new selective chemical inhibitor of mutant isocitrate dehydrogenase-1. J Cancer Prev 20:78–83. https://doi.org/10.15430/JCP.2015.20.1.78
Kim E, ten Hacken E, Sivina M et al (2020) The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia 34:1588–1598. https://doi.org/10.1038/s41375-019-0682-7
Knoepfler PS, Zhang X, Cheng PF et al (2006) Myc influences global chromatin structure. EMBO J 25:2723–2734. https://doi.org/10.1038/sj.emboj.7601152
Kooistra SM, Helin K (2012) Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 13:297–311. https://doi.org/10.1038/nrm3327
Kudo Y, Tateishi K, Yamamoto K et al (2012) Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci 103:670–676. https://doi.org/10.1111/j.1349-7006.2012.02213.x
Lai C-J, Bao R, Tao X et al (2010) CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 70:3647–3656. https://doi.org/10.1158/0008-5472.CAN-09-3360
Leal AS, Williams CR, Royce DB et al (2017) Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Lett 394:76–87. https://doi.org/10.1016/j.canlet.2017.02.021
Lee H-Z, Kwitkowski VE, Valle PLD et al (2015) FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res 21:2666–2670. https://doi.org/10.1158/1078-0432.CCR-14-3119
Li X, Kazgan N (2011) Mammalian sirtuins and energy metabolism. Int J Biol Sci 7:575–587. https://doi.org/10.7150/ijbs.7.575
Li B, Qiu B, Lee DSM et al (2014) Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature 513:251–255. https://doi.org/10.1038/nature13557
Li H, Zhang X, Jin Z et al (2019) MiR-122 promotes the development of colon cancer by targeting ALDOA in vitro. Technol Cancer Res Treat 18:1533033819871300. https://doi.org/10.1177/1533033819871300
Li C, Yu Z, Ye J (2020a) MicroRNA-513a-3p regulates colorectal cancer cell metabolism via targeting hexokinase 2. Exp Ther Med 20:572–580. https://doi.org/10.3892/etm.2020.8727
Li L, Yang L, Fan Z et al (2020b) Hypoxia-induced GBE1 expression promotes tumor progression through metabolic reprogramming in lung adenocarcinoma. Signal Transduct Target Ther 5:54. https://doi.org/10.1038/s41392-020-0152-8
Ling Z, Liu D, Zhang G et al (2017) miR-361-5p modulates metabolism and autophagy via the Sp1- mediated regulation of PKM2 in prostate cancer. Oncol Rep 38:1621–1628. https://doi.org/10.3892/or.2017.5852
Liu PY, Xu N, Malyukova A et al (2013) The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ 20:503–514. https://doi.org/10.1038/cdd.2012.147
Liu X-S, Little JB, Yuan Z-M (2015) Glycolytic metabolism influences global chromatin structure. Oncotarget 6:4214–4225. https://doi.org/10.18632/oncotarget.2929
Liu C, Cai L, Li H (2019) miR-185 regulates the growth of osteosarcoma cells via targeting hexokinase 2. Mol Med Rep 20:2774–2782. https://doi.org/10.3892/mmr.2019.10534
Lopez-Serra P, Marcilla M, Villanueva A et al (2014) A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Nat Commun 5. https://doi.org/10.1038/ncomms4608
Lu H, Buchan RJ, Cook SA (2010) MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res 86:410–420. https://doi.org/10.1093/cvr/cvq010
Lu C, Ward PS, Kapoor GS et al (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474–478. https://doi.org/10.1038/nature10860
Luo L, Xiao L, Lian G et al (2020) miR-125a-5p inhibits glycolysis by targeting hexokinase-II to improve pulmonary arterial hypertension. Aging (Albany NY) 12:9014–9030. https://doi.org/10.18632/aging.103163
Mentch SJ, Mehrmohamadi M, Huang L et al (2015) Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. Cell Metab 22:861–873. https://doi.org/10.1016/j.cmet.2015.08.024
Mertz JA, Conery AR, Bryant BM et al (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. PNAS 108:16669–16674. https://doi.org/10.1073/pnas.1108190108
miRagen Therapeutics, Inc. (2020) A phase 1 dose-ranging study to investigate the safety, tolerability, and pharmacokinetics of MRG-106 following local intratumoral, subcutaneous, and intravenous administration in subjects with various lymphomas and leukemias. clinicaltrials.gov
Miranda TB, Cortez CC, Yoo CB et al (2009) DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8:1579–1588. https://doi.org/10.1158/1535-7163.MCT-09-0013
Moros A, RodrÃguez V, Saborit-Villarroya I et al (2014) Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia 28:2049–2059. https://doi.org/10.1038/leu.2014.106
Moussaieff A, Rouleau M, Kitsberg D et al (2015) Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. Cell Metab 21:392–402. https://doi.org/10.1016/j.cmet.2015.02.002
Myers SA, Panning B, Burlingame AL (2011) Polycomb repressive complex 2 is necessary for the normal site-specific O-GlcNAc distribution in mouse embryonic stem cells. Proc Natl Acad Sci U S A 108:9490–9495. https://doi.org/10.1073/pnas.1019289108
Nakajima K, Kawashima I, Koshiisi M et al (2019) Glycolytic enzyme hexokinase II is a putative therapeutic target in B-cell malignant lymphoma. Exp Hematol 78:46–55.e3. https://doi.org/10.1016/j.exphem.2019.09.023
National Cancer Institute (NCI) (2021) A phase 1b trial of CB-839 in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma. clinicaltrials.gov
Nguyen TTT, Zhang Y, Shang E et al (2020a) HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. J Clin Investig 130:3699–3716. https://doi.org/10.1172/JCI129049
Nguyen TTT, Zhang Y, Shang E et al (2020b) HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. J Clin Invest 130:3699–3716. https://doi.org/10.1172/JCI129049
Nie Z-Y, Liu X-J, Zhan Y et al (2019) miR-140-5p induces cell apoptosis and decreases Warburg effect in chronic myeloid leukemia by targeting SIX1. Biosci Rep 39:BSR20190150. https://doi.org/10.1042/BSR20190150
Novartis Pharmaceuticals (2020) A phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations. clinicaltrials.gov
Oncoethix GmbH (2018) A phase I, dose-finding study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Haematological Malignancies. clinicaltrials.gov
Oncoethix GmbH (2019) A phase IB trial with OTX015/MK-8628, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) proteins, in patients with selected advanced solid tumors. clinicaltrials.gov
Pan D, Mao C, Wang Y-X (2013) Suppression of gluconeogenic gene expression by LSD1-mediated histone demethylation. PLoS One 8:e66294. https://doi.org/10.1371/journal.pone.0066294
Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23:27–47. https://doi.org/10.1016/j.cmet.2015.12.006
Peschiaroli A, Giacobbe A, Formosa A et al (2013) miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene 32:797–802. https://doi.org/10.1038/onc.2012.100
Pinho SS, Reis CA (2015) Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 15:540–555. https://doi.org/10.1038/nrc3982
Pollard PJ, Wortham NC, Tomlinson IPM (2003) The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Ann Med 35:632–639. https://doi.org/10.1080/07853890310018458
Pollyea DA, Stevens BM, Jones CL et al (2018) Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med 24:1859–1866. https://doi.org/10.1038/s41591-018-0233-1
Popovici-Muller J, Lemieux RM, Artin E et al (2018) Discovery of AG-120 (Ivosidenib): a first-in- class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett 9:300–305. https://doi.org/10.1021/acsmedchemlett.7b00421
Qanungo S, Haldar S, Basu A (2003) Restoration of silenced Peutz-Jeghers syndrome gene, LKB1, induces apoptosis in pancreatic carcinoma cells. Neoplasia 5:367–374. https://doi.org/10.1016/S1476-5586(03)80030-1
Querfeld C, Pacheco T, Foss FM et al (2016) Preliminary results of a phase 1 trial evaluating MRG- 106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, in patients with CTCL. Blood 128:1829–1829. https://doi.org/10.1182/blood.V128.22.1829.1829
Raedler LA (2016) Farydak (Panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma. Am Health Drug Benefits 9:84–87
Rathore MG, Saumet A, Rossi J-F et al (2012) The NF-κB member p65 controls glutamine metabolism through miR-23a. Int J Biochem Cell Biol 44:1448–1456. https://doi.org/10.1016/j.biocel.2012.05.011
Rawluszko AA, Bujnicka KE, Horbacka K et al (2013) Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer. BMC Cancer 13:526. https://doi.org/10.1186/1471-2407-13-526
Richardson PG, Laubach JP, Lonial S et al (2015) Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther 15:737–748. https://doi.org/10.1586/14737140.2015.1047770
Robertson KD, Uzvolgyi E, Liang G et al (1999) The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 27:2291–2298. https://doi.org/10.1093/nar/27.11.2291
Robinson MM, McBryant SJ, Tsukamoto T et al (2007) Novel mechanism of inhibition of rat kidney- type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J 406:407–414. https://doi.org/10.1042/BJ20070039
Röhrig F, Schulze A (2016) The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer 16:732–749. https://doi.org/10.1038/nrc.2016.89
Rothbart SB, Strahl BD (2014) Interpreting the language of histone and DNA modifications. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1839:627–643. https://doi.org/10.1016/j.bbagrm.2014.03.001
Sakabe K, Hart GW (2010) O-GlcNAc transferase regulates mitotic chromatin dynamics. J Biol Chem 285:34460–34468. https://doi.org/10.1074/jbc.M110.158170
Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279:2610–2623. https://doi.org/10.1111/j.1742-4658.2012.08644.x
Sawas A, Radeski D, O’Connor OA (2015) Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol 6:202–208. https://doi.org/10.1177/2040620715592567
Sebastián C, Zwaans BMM, Silberman DM et al (2012) The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151:1185–1199. https://doi.org/10.1016/j.cell.2012.10.047
Seto AG, Beatty X, Lynch JM et al (2018) Cobomarsen, an oligonucleotide inhibitor of miR-155, co- ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol 183:428–444. https://doi.org/10.1111/bjh.15547
Sharma S, Symanowski J, Wong B et al (2008) A phase II clinical trial of Oral Valproic acid in patients with castration-resistant prostate cancers using an intensive biomarker sampling strategy. Transl Oncol 1:141–147
Shin J, He M, Liu Y et al (2013) SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep 5:654–665. https://doi.org/10.1016/j.celrep.2013.10.007
Siegel MB, Davare MA, Liu SQ et al (2014) The Bromodomain inhibitor CPI203 demonstrates preclinical synergistic activity with Bortezomib in drug resistant myeloma. Blood 124:4702–4702. https://doi.org/10.1182/blood.V124.21.4702.4702
Siu KT, Ramachandran J, Yee AJ et al (2017) Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia 31:1760–1769. https://doi.org/10.1038/leu.2016.355
Song D, Ni J, Xie H et al (2014) DNA demethylation in the PTEN gene promoter induced by 5- azacytidine activates PTEN expression in the MG-63 human osteosarcoma cell line. Exp Ther Med 7:1071–1076. https://doi.org/10.3892/etm.2014.1571
Stathis A, Zucca E, Bekradda M et al (2016) Clinical response of carcinomas harboring the BRD4- NUT Oncoprotein to the targeted Bromodomain inhibitor OTX015/MK-8628. Cancer Discov 6:492–500. https://doi.org/10.1158/2159-8290.CD-15-1335
Strand KA, Sizhao L, Mutryn MF et al (2020) High throughput screen identifies the DNMT1 (DNA Methyltransferase-1) inhibitor, 5-Azacytidine, as a potent inducer of PTEN (phosphatase and Tensin homolog). Arterioscler Thromb Vasc Biol 40:1854–1869. https://doi.org/10.1161/ATVBAHA.120.314458
Sun X, Zhang L (2017) MicroRNA-143 suppresses oral squamous cell carcinoma cell growth, invasion and glucose metabolism through targeting hexokinase 2. Biosci Rep 37:BSR20160404. https://doi.org/10.1042/BSR20160404
Sun W, Zhao L, Song X et al (2017a) MicroRNA-210 modulates the cellular energy metabolism shift during H2O2-induced oxidative stress by repressing ISCU in H9c2 cardiomyocytes. CPB 43:383–394. https://doi.org/10.1159/000480417
Sun Z, Zhang W, Li Q (2017b) miR-125a suppresses viability and glycolysis and induces apoptosis by targeting hexokinase 2 in laryngeal squamous cell carcinoma. Cell Biosci 7:51. https://doi.org/10.1186/s13578-017-0178-y
Tahiliani M, Koh KP, Shen Y et al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930–935. https://doi.org/10.1126/science.1170116
Tang S-W, Yang T-C, Lin W-C et al (2011) Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis 32:138–145. https://doi.org/10.1093/carcin/bgq225
Teng Y, Zhang Y, Qu K et al (2015) MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3. Oncotarget 6:40799–40814. https://doi.org/10.18632/oncotarget.5695
Thomas MG, Saldanha M, Mistry RJ et al (2013) Nicotinamide N-methyltransferase expression in SH-SY5Y neuroblastoma and N27 mesencephalic neurones induces changes in cell morphology via ephrin-B2 and Akt signalling. Cell Death Dis 4:e669. https://doi.org/10.1038/cddis.2013.200
Turcan S, Rohle D, Goenka A et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479–483. https://doi.org/10.1038/nature10866
Ulanovskaya OA, Zuhl AM, Cravatt BF (2013) NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol 9:300–306. https://doi.org/10.1038/nchembio.1204
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033. https://doi.org/10.1126/science.1160809
Vázquez R, Riveiro ME, Astorgues-Xerri L et al (2016) The bromodomain inhibitor OTX015 (MK- 8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Oncotarget 8:7598–7613. https://doi.org/10.18632/oncotarget.13814
Venneti S, Felicella MM, Coyne T et al (2013) Histone 3 lysine 9 Trimethylation is differentially associated with Isocitrate dehydrogenase mutations in Oligodendrogliomas and high-grade Astrocytomas. J Neuropathol Exp Neurol 72:298–306. https://doi.org/10.1097/NEN.0b013e3182898113
Wang J-B, Erickson JW, Fuji R et al (2010) Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18:207–219. https://doi.org/10.1016/j.ccr.2010.08.009
Wang F, Travins J, DeLaBarre B et al (2013) Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340:622–626. https://doi.org/10.1126/science.1234769
Wang D, Meng G, Zheng M et al (2016) The Glutaminase-1 inhibitor 968 enhances Dihydroartemisinin-mediated antitumor efficacy in hepatocellular carcinoma cells. PLoS One 11:e0166423. https://doi.org/10.1371/journal.pone.0166423
Warburg O (1956) On the origin of cancer cells. Science 123:309–314. https://doi.org/10.1126/science.123.3191.309
Wardell SE, Ilkayeva OR, Wieman HL et al (2009) Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 23:388–401. https://doi.org/10.1210/me.2008-0179
Wise DR, DeBerardinis RJ, Mancuso A et al (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 105:18782–18787. https://doi.org/10.1073/pnas.0810199105
Wong CC, Qian Y, Yu J (2017) Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches. Oncogene 36:3359–3374. https://doi.org/10.1038/onc.2016.485
Wu Y, Siadaty MS, Berens ME et al (2008) Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N- methyltransferase as novel regulators of cell migration. Oncogene 27:6679–6689. https://doi.org/10.1038/onc.2008.264
Wu H, Wang Y, Wu C et al (2016) Resveratrol induces cancer cell apoptosis through MiR- 326/PKM2-mediated ER stress and mitochondrial fission. J Agric Food Chem 64:9356–9367. https://doi.org/10.1021/acs.jafc.6b04549
Wyce A, Degenhardt Y, Bai Y et al (2013) Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget 4:2419–2429. https://doi.org/10.18632/oncotarget.1572
Xie F, Huang M, Lin X et al (2018) The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine. Sci Rep 8:8102. https://doi.org/10.1038/s41598-018-26496-0
Xu W, Yang H, Liu Y et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α- ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30. https://doi.org/10.1016/j.ccr.2010.12.014
Yamasaki T, Seki N, Yoshino H et al (2013) Tumor-suppressive microRNA-1291 directly regulates glucose transporter 1 in renal cell carcinoma. Cancer Sci 104:1411–1419. https://doi.org/10.1111/cas.12240
Yang H, Liu Y, Bai F et al (2013) Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32:663–669. https://doi.org/10.1038/onc.2012.67
Yang J, Jin X, Yan Y et al (2017a) Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression. Sci Rep 7:43864. https://doi.org/10.1038/srep43864
Yang J, Jin X, Yan Y et al (2017b) Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression. Sci Rep 7:43864. https://doi.org/10.1038/srep43864
Yoshino H, Enokida H, Itesako T et al (2013) Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in renal cell carcinoma. Cancer Sci 104:1567–1574. https://doi.org/10.1111/cas.12280
Yu X, Li S (2017) Non-metabolic functions of glycolytic enzymes in tumorigenesis. Oncogene 36:2629–2636. https://doi.org/10.1038/onc.2016.410
Yu G, Sun W, Shen Y et al (2018) PKM2 functions as a potential oncogene and is a crucial target of miR-148a and miR-326 in thyroid tumorigenesis. Am J Transl Res 10:1793–1801
Yuan L, Sheng X, Clark LH et al (2016) Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer. Am J Transl Res 8:4265–4277
Zhang Y, Reinberg D (2001) Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 15:2343–2360. https://doi.org/10.1101/gad.927301
Zhang J, Wang Y, Li G et al (2014) Down-regulation of nicotinamide N-methyltransferase induces apoptosis in human breast cancer cells via the mitochondria-mediated pathway. PLoS One 9:e89202. https://doi.org/10.1371/journal.pone.0089202
Zheng B, Yao Y, Liu Z et al (2013) Crystallographic investigation and selective inhibition of mutant Isocitrate dehydrogenase. ACS Med Chem Lett 4:542–546. https://doi.org/10.1021/ml400036z
Zhong L, D’Urso A, Toiber D et al (2010) The histone deacetylase SIRT6 regulates glucose homeostasis via Hif1α. Cell 140:280. https://doi.org/10.1016/j.cell.2009.12.041
Zhou T, Meng X, Che H et al (2016) Regulation of insulin resistance by multiple MiRNAs via targeting the GLUT4 Signalling pathway. Cell Physiol Biochem 38:2063–2078. https://doi.org/10.1159/000445565
Zwaans BMM, Lombard DB (2014) Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming. Dis Model Mech 7:1023–1032. https://doi.org/10.1242/dmm.016287
Acknowledgements
Work in the RT lab is supported by the National Medical Research Council (NMRC) Grant NMRC/OFIRG/0073/201 and the Ministry of Education (MOE) MOE2019-T2-1-024. All images were created with BioRender.com.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Das, D., Karthik, N., Taneja, R. (2022). Epigenetic Small-Molecule Modulators Targeting Metabolic Pathways in Cancer. In: Kundu, T.K., Das, C. (eds) Metabolism and Epigenetic Regulation: Implications in Cancer. Subcellular Biochemistry, vol 100. Springer, Cham. https://doi.org/10.1007/978-3-031-07634-3_16
Download citation
DOI: https://doi.org/10.1007/978-3-031-07634-3_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-07633-6
Online ISBN: 978-3-031-07634-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)